Steering Committee

MMRC research efforts are selected and overseen by a dynamic team of experts in the field of multiple myeloma, including representation from world-renowned MMRC Member Institutions as well as key leadership from the Multiple Myeloma Research Foundation. This multidisciplinary team, with expertise in the fields of multiple myeloma research, clinical care, and executive leadership, provides both strategic direction and scientific oversight to the Consortium.

		Kenneth Anderson, MD - Chair Chief, Division of Hematologic Neoplasia Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Dr. Anderson graduated from Johns Hopkins Medical School. He trained in internal medicine at Johns Hopkins Hospital and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School and serves as Chief of the Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at the Dana-Farber Cancer Institute. He received the Waldenstrom's Award in 2003 for his translational research directed to the development of novel therapeutics targeting the myeloma cell in its microenvironment. He serves as Chair of the National Comprehensive Cancer Network's Multiple Myeloma Clinical Practice Guidelines Committee, on the Board of Directors and as Chairman of the Scientific Advisors of the Multiple Myeloma Research Foundation, and is a Doris Duke Distinguished Clinical Research Scientist

		Bill Dalton, PhD, MD Chief Executive Officer and Center Director H. Lee Moffitt Cancer Center & Research Institute Dr. Dalton received his PhD in toxicology and medical life sciences and his degree in medicine from Indiana University. He completed his internship in internal medicine at Indiana University and his residency in medicine at the University of Arizona in Tucson. Dr. Dalton was the Founding Director of the Bone Marrow Transplant Program at the University of Arizona. From 1997 to 2001, he was Deputy Director of the H. Lee Moffitt Cancer Center & Research Institute and the Chairman of the Department of Interdisciplinary Oncology at the University of South Florida. He served as Dean of the College of Medicine at the University of Arizona in Tucson from 2001 to 2002. In August 2002, Dr. Dalton was appointed the Chief Executive Officer and Center Director of H. Lee Moffitt Cancer Center & Research Institute. Dr. Dalton's research interests include biochemical mechanisms of drug resistance and new drug discovery in multiple myeloma.

		Kathy Giusti Founder and Chief Executive Officer Multiple Myeloma Research Foundation (MMRF) Multiple Myeloma Research Consortium (MMRC) Kathy Giusti is the Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). Shortly after being diagnosed witih multiple myeloma, an incurable blood cancer, founded the MMRF in 1998 to fund innovative myeloma research and drug discovery. She then founded the MMRC in 2004 to enable leading research institutions to work with industry to speed the discovery and development of effective new treatments for myeloma. A graduate of Harvard Business School with an MBA in general management, Kathy began her career with Merck & Co., and later joined the Gillette Company. She then joined G.D. Searle & Co., where she last served as Executive Director of Searle's worldwide arthritis franchise. Kathy has received the 1998 Healthcare Businesswomen's Association's Woman of the Year Award, the 2001 Harvard Business School Entrepreneurial Award, the 2002 McCarty Cancer Foundation Humanitarian Award, the 2002 Joseph Michaeli Award from the Weill Medical College of Cornell University, the 2005 Harvard Business School Award for Courage and Valor, and the 2006 Partners in Progress Award from the American Society of Clinical Oncology. Kathy has served on the Institute of Medicine's National Cancer Policy Board and the Cancer Leadership Council. She currently serves on the National Cancer Advisory Board, having been appointed to the position by President Bush, the Board of Directors for IMS Health, and is a member of the Health Research Alliance. Most recently, Kathy's efforts to advance cancer research and drug development have been featured in The Wall Street Journal and on NBC Nightly News.

		A. Keith Stewart, MD Professor Mayo Clinic College of Medicine Dr. Stewart graduated from Medical School at the University of Aberdeen in Scotland. He trained in Internal Medicine at Queen's University in Kingston, Ontario, and specialized in Hematology and Oncology at the University of Toronto, and as a Medical Research Council Fellow at the New England Medical Centre in Boston. In 2002, Dr. Stewart also obtained an MBA from Ivey Business School at the University of Western Ontario and was recognized as one of Canada's top 40 under 40. Dr. Stewart was a consultant at the Toronto General and Princess Margaret Hospitals, University of Toronto, from 1992-2005, where he held the Scott-Whitmore Chair in Hematology. He was appointed the inaugural director of the McLaughlin Centre for Molecular Medicine at the University of Toronto, in 2002. In 2005 Dr. Stewart relocated to the Mayo Clinic -Scottsdale, where he is a Professor of medicine. He is a member of the scientific advisory board of the Multiple Myeloma Research Foundation, and a founding member of the Multiple Myeloma Research Consortium.